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Introduction
Accurate measurement of drug molecule concentrations in blood plasma samples is essential for pharmacokinetic and toxicokinetic studies in drug discovery and development (Li et al., 2011; Rozeta et al., 2011) . Correct identification of metabolites in plasma samples is critical for safety assessment of a drug candidate (Ma and Chowdhury, 2011; Penner et al. 2012; Gao et al. 2013) . The occurrence of ex vivo instability complicates the analysis by making metabolite identities insecure and measured drug concentrations uncertain. While the instability of some molecules could be predicted by the presence of certain chemically or biologically labile moieties (Li et al., 2011; Mitchell, 2014; Erve 2008) , in other cases ex vivo instability can be unexpected.
One such unexpected instability was discovered during the preclinical development of an inhaled drug candidate AZD9819 (Lindsjö, 2011) , an inhibitor of human neutrophil elastase for potential treatment of chronic obstructive pulmonary disease (Sjö, 2012; Lucas et al., 2013) . A mono-oxidation product of AZD9819 was detected in plasma ex vivo and in vitro. The occurrence of this oxidation was empirically prevented by acidification following plasma sample collection (e.g., with 2M phosphoric acid added at approximately 1.5% of the plasma volume) in preclinical and clinical development studies. Two intriguing findings emerged from our investigation of this otherwise seemingly simple mono-oxidation. First, the mono-oxidation product was in fact a drastically rearranged oxidation product (ROP). Second, we pinpointed lipid peroxides as the cause of the initial epoxidation step in our proposed mechanism of ROP formation. This cause of oxidation of drug molecules in blood plasma has not been reported previously.
The ROP formation is distinct in terms of both the cause of oxidation and subsequent rearrangements from two previous reports of rearranged oxidative metabolites of pyrazinone-containing thrombin inhibitors developed at Merck Subramanian et al., 2003) . Oxidative rearrangements in the Merck cases occurred via cytochrome P450-mediated epoxidation at the C=C bond in a pyrazinone ring (of 3-amino-6-methyl-pyrazinone and 3-amino-6-chloro-pyrazinone derivatives) Subramanian et al., 2003) . This is no surprise because P450 enzymes are known to be capable of epoxidation (Parkinson, 2001; Guengerich, 2007) . However 
MATERIALS AND METHODS
6-(1-(4-cyanophenyl)-1H-pyrazol-5-yl)-N-ethyl-5-methyl-3-oxo-4-(3-(trifluoromethyl)phenyl)-3,4-
dihydropyrazine-2-carboxamide (AZD9819) was synthesized by a reported procedure (Lindsjö, 2011 14.5, 18.7, 33.6, 109.3, 111.2, 118.5, 122.5, 123 .7 (q, J = 272.5 Hz) 123.9, 124.8 (q, J = 3.5 Hz), 126.6 (q, J = 3.6 Hz), 130.5 (q, J = 32.6 Hz), 131.3, 132.0, 133.4, 137.4, 138.4, 141.2, 142.4, 143.0, 143.3, 154.4, 161.3 . Sodium perborate tetrahydrate (0.38 g, 0.0024 mol) was dissolved in water (20 mL) and added slowly to the reaction mixture over approximately 3 hours. During the addition, the pH of the reaction mixture was maintained at 8 by the addition of 0.1 M hydrochloric acid solution. After addition of the perborate, the reaction was stirred for 20 hours, diluted with water (100 mL) and extracted with dichloromethane (2 x 50 mL). The combined dichloromethane extracts were washed with water (2 x 50 mL), dried over anhydrous sodium sulfate and evaporated under reduced pressure to leave the product ROP as a white powder. 124.3, 125.9, 126.5, 129.4 (q, J = 31.6 Hz), 129.8, 129.9, 133.5, 138.8, 141.9, 142.7, 148.5, 149.8, 158.2, 169.3 
. (Complete assignment available in
This article has not been copyedited and formatted. The final version may differ from this version. dram glass vial with a rubber septum at room temperature. Two stainless steel syringe needles were inserted through the septum, with one into the plasma mixture for purging and the other above the liquid level for venting.
The plasma mixture and the vial were slowly purged with
18
O 2 for approximately 5 min. Some plasma mixture was lost through the needle venting to the air due to foaming. Both needles were removed from the septum and the vial was then incubated at 37 °C for 2 h. The reaction was stopped with MeCN (approx. 2:1; v:v) .
Plasma incubations of AZD9819 in the presence of NaN 3 , allopurinol, KCN, ascorbic acid, or reduced Lglutathione (GSH). AZD9819 at 15 µM was incubated at 37 °C in rat or dog plasma in the presence of NaN 3 (up to 50 mM), in rat, dog or human plasma in the presence of 100 µM allopurinol, in rat plasma in the presence of 50 mM KCN, in rat or dog plasma with ascorbic acid added (up to 50 mM), and in rat, dog, and human plasma with GSH added (up to 50 mM). The pH of plasma samples with added GSH or ascorbic acid was verified to be still above pH 7 with pH test paper. As control, 15 µM AZD9819 was incubated in the plasma of respective species.
The incubation volume was 250 µL. The incubations were terminated at 2 h by adding twice volume of MeCN.
This article has not been copyedited and formatted. The final version may differ from this version. Catalase pretreated plasma. 250-uL rat plasma was pre-incubated with 1000 unit/mL bovine liver catalase at 37 °C for 30 min. Then AZD9819 was added at 15 µM and the incubation was continued for 2 h before being terminated by adding twice volume of MeCN. As a control, 15 µM AZD9819 was incubated in untreated rat plasma, including a pre-incubation at 37 °C for 30 min. without catalase. The effectiveness of the catalase was confirmed by incubation with 500 µM H 2 O 2 in pH 7.4 buffer when the reactivity of the H 2 O 2 was completely eliminated.
Incubation of AZD9819 with human hemoglobin in the absence/presence of H 2 O 2 . AZD9819 at 15 µM was incubated at 37 °C with 100 µM human hemoglobin in a 100 mM pH 7.4 phosphate buffer, with the 100 µM hemoglobin in the presence of 500 µM H 2 O 2 , or with 500 µM H 2 O 2 alone in the buffer. After 2 h, bovine liver catalase was added to the incubation mixture at 1000 unit/mL, followed by additional 15-minute incubation. As a negative control, a 500 µM H 2 O 2 in the buffer was pre-incubated with 1000 unit/mL for 15 minute before AZD9819 was added. At the end of all incubations, twice the volume of MeCN containing 1% formic acid was added to the incubation mixture.
column (Aberdeen, Scotland, UK). The mobile phases consisted of (A) MeCN:H 2 O (5:95) and (B) MeCN:H 2 O (95:5). Both solvents contained 0.1% formic acid. The LC gradient started at 5% B, increased linearly to 25% B during the first minute and then to 65% B over the next 24 minutes. It was then increased to 100% B at 26 min and retained for 3 minutes, finally decreased to 5% B at 30 min. The flow rate was 1 mL/min of LC mobile phase and 3 mL/min of liquid scintillation cocktail.
An LC system of the same type as above was used in line with a Q-ToF Premier mass spectrometer (Waters, Wilmslow, UK) equipped with LockSpray interface and electrospray probe. The LC-MS and MS/MS analysis utilized the same type but a smaller LC column (50 x 2.1 mm), and the same LC mobile phases as above with similar but short gradients at the flow rate of 0.25 mL/min. MS/MS was performed at 30-eV collision energy with argon as collision gas.
LC-UV-MS and MS/MS of non-radiolabeled AZD9819 incubation products. After centrifugation of
terminated incubation mixtures to pellet proteins, aliquots of 10 or 15 µL supernatant samples were injected into an LC-UV-MS system, consisting of an Acquity UPLC system (Waters, Milford, MA) and an LTQ-Orbitrap XL high resolution mass spectrometer (Thermo Scientific, San Jose, CA). An ACE C18, 3 μm, 150x2.1 mm column was used for LC separation. The mobile phases at the flow rate of 0.2 mL/min consisted of (A) water and (B)
acetonitrile. Both solvents contained 0.1% formic acid. The LC gradient started at 5% B, increased linearly to 25% during the first minute and then to 65% B over the next 24 minutes. It was then increased to 100% B at 26 min and retained for 3 minutes, finally decreased to 5% B at 30 min. The UV wavelength at 268 nm with 6nm resolution was monitored in acquisition of UV chromatograms and photodiode array UV spectra of 200 to 500 nm were also acquired.
LC-MS spectra were acquired at the resolution of 30,000. Collision-induced dissociation (CID) with helium as collision gas in the linear Ion trap, or the instrument manufacturer's named "high energy collision-induced dissociation" (HCD) with nitrogen as collision gas in the HCD cell, was used in acquisition of MS/MS spectra by 
RESULTS
Figure 1 shows radiochromatographic profiles of rat, dog, and human plasma generated products of chromatograms demonstrating ROP formation in plasma samples were acquired. We have chosen to present the radiochromatograms here as they convincingly demonstrate that ROP is the sole direct product of the parent compound AZD9819. The deacetyl-ROP that occurred mainly in rat plasma was shown to be an enzymatic hydrolysis product of ROP (described later). Interestingly we were able to synthesize an authentic standard of ROP before we even knew what the structure was. The choice of synthetic method resulted from preliminary work using a commercial peroxidase in the presence of H 2 O 2 (Coprinus cinereus peroxidase recombinant in an aspergillus, supplied by Novozymes, Denmark), to make a similar oxidation product of an analog compound (details of the analog compound not provided for proprietary reasons). ROP was made from AZD9819 at high yield by reaction with sodium perborate in MeCN:H 2 O (Experimental Section). The synthetic standard was unambiguously proven to be identical to ROP generated in plasma, by a perfect match in LC-UV-MS/MS (retention time, UV spectra, and high resolution MS/MS spectra showing the accurate mass of fragment ions.
Supplemental Figure 5 ). It was also verified that the plasma-generated [ 14 C]ROP and non-radiolabeled ROP at our different laboratories have the same chemical structure, by matching all LC-MS/MS fragmentations (Supplemental Figure 6 ).
Even after a high-purity standard was synthesized, it was still challenging to elucidate the structure. ROP does not share any similar fragmentation with AZD9819 in MS/MS (Supplemental Figures 5 and 6 ) and the lack of protons at the center core of ROP means that the presence of a new oxazole ring cannot be proven directly by NMR. Hence a number of putative structures (Supplemental Figure 7) , including those we could envisage arose from possible rearrangement mechanisms following an initial oxidation, were proposed to generate hypothetical products to match NMR and MS/MS data (Supplemental Figures 3, 4 , 5, and 6). The majority of these putative Scheme 1 shows the deduced structure for ROP and the proposed oxidative rearrangement mechanism for its formation, by putting all the information together. The cause of the initial oxidation and other details of the mechanism will be discussed later. A key part of structural elucidation process was the use of predicted 13 C chemical shifts, and a comparison is shown in Table 1 illustrating the change in chemical shift of carbon atoms which map from AZD9819 to ROP (Scheme 1), and how well they match predicted values. Heteronuclear
Multiple Bond Correlation (HMBC) NMR correlation data was also useful. For example, Figure 2 shows a portion of the HMBC spectrum of the ROP synthetic standard. The correlations observed, specifically between H33 and the carbonyl C34 of the acetyl, prove the position of the acetyl group in ROP and led us to propose the transfer of this group in the mechanism (4 to 5 in Scheme 1). We were subsequently able to obtain an X-ray structure from a single crystal of the synthetic standard to further corroborate the structural identification ( Figure   3 ). O 2 is incorporated to the location predicted by the proposed oxidative rearrangement mechanism. In the LC-MS spectrum of rat plasma generated ROP ( Figure 4A ), the naturally occurring isotopic peak at m/z 511 (i.e. 2 Da higher than the monoisotopic peak at m/z 509) has a low relative abundance of less than 5%. When ROP was not produced by cytochrome P450 in liver, as it was absent from incubations of AZD9819 in rat, dog, and human hepatocytes (data not shown). In search for the cause of the oxidation of AZD9819 in plasma, a number of experiments applying different reagents or experimental conditions to the incubations in plasma were performed and are summarized in Table 2 . The percentages in the table were estimated from LC-UV peak areas with consideration of the different UV response of ROP vs. AZD9819 (with an absorbance ratio of approximately 1.5 at 268 nm). Additionally, it was assumed that deacetyl-ROP observed mainly in rat plasma has the same UV absorbance as ROP. The percentage values in Table 2 are intended for qualitative comparison and along with the other experiments described here, helped guide us to the cause of the oxidation.
The formation of ROP was not a simple chemical degradation process, because ROP was not produced in any of the control incubations of AZD9819 in blank buffer solutions. It was also not a photo oxidative process, because the use of an amber vial or wrapping a vial in aluminum foil gave the same yield of ROP as the control incubation in a clear vial under ambient light (Table 2 ).
We considered a few possible enzymatic causes. Peroxidases are known to catalyze epoxidation of C=C bonds by peroxides such as H 2 O 2 (Adam et al., 1999; Ortiz de Montellano, 1992) . Indeed, as stated earlier, we made a similar oxidation product of an analog compound using a commercial peroxidase. However, the oxidation of AZD9819 in plasma is not inhibited by sodium azide (NaN 3 , Table 2 ), a known inhibitor of peroxidases (Ortiz de Montellano, 1992; Pozdnyakova, 2013) . We also excluded xanthine oxidase (XO). Kalgutkar and co-workers have reported a XO mediated oxidation of a quinoxaline derivative in rodent plasma (Sharma et al., 2011) Montellano, 1996) and retinoic acid (Iwahashi et al., 1985) offered a possible cause if hemolysis had occurred and released hemoglobin into the plasma. In both cases the reaction was effectively inhibited by cyanide ions (Ortiz de Montellano et al., 1985; Iwahashi et al., 1985) . However in our case, KCN enhanced rather than inhibited ROP formation (Table 2) . Furthermore, incubation of 15 µM AZD9819 with 100 µM human hemoglobin did not produce any ROP, and the incubation of AZD9819 in 100 µM hemoglobin in the presence of 500 µM H 2 O 2 did not catalyze the reaction (data not shown).
The formation of ROP from AZD9819 was most likely an ex vivo and in vitro phenomenon. During preclinical and clinical development, metabolite identification was conducted in rat/dog plasma, urine, feces and bile samples rat, >93% in dog) suggested that it was unlikely that ROP or its intermediates were formed but then bound to macromolecules in vivo.
The effect of temperature on ROP formation was revealing ( Table 2 ). The drop in yield from 37°C to room temperature might not be as great as would be expected for an enzymatic reaction and ROP formation was not completely eliminated even on ice. Inactivation of rat plasma at 56 °C for 1 h did not prevent the ROP formation from AZD9819 (Table 2 ), but abolished formation of deactyl-ROP from ROP synthetic standard suggesting deacetyl-ROP is an enzymatic product of ROP (Supplemental Figure 9) . In contrast, denaturing the plasma with MeCN did eliminate ROP formation (Table 2) . Collectively, these observations suggested the likely involvement of heat-resistant proteins. However, we did not realize that these could be lipoproteins until lipid peroxides emerged to be the probable cause from subsequent experiments.
ROP did not appear to be produced by H 2 O 2 oxidation in plasma, because the incubation of 15 µM AZD9819 with up to 500 µM H 2 O 2 in pH7.4 buffer only produced a trace amount of ROP (less than 1% of parent, data not shown). Moreover, pre-treatment of rat plasma with bovine liver catalase at 1000 unit/mL, which would decompose any H 2 O 2 present in the plasma, did not abolish the oxidation of AZD9819 (Table 2) . We also ruled out the formation of ROP by hydroxyl radical or hydroperoxyl radical from H 2 O 2 , because ROP was not formed by the Fenton reaction of AZD9819 with 100 µM H 2 O 2 and 100 µM ferrous ion (Fe 2+ ) in a pH4.5 buffer (within the optimal pH 3-6 range of the Fenton reaction). Intriguingly, during these experiments we made the fortuitous discovery that ROP could be produced from AZD9819, albeit alongside other oxidative products, using a very high concentration of H 2 O 2 (90 mM) in pH 7.4 phosphate buffer (Supplemental Figure 10) . This hinted that even if H 2 O 2 was not involved in ROP formation in plasma, perhaps other peroxides might be.
Ascorbic acid (one form of vitamin C) was tested to determine whether a radical mechanism could be involved.
Inhibition was modest at 1 mM, but significant at 50 mM (Table 2 ). We were unaware that ascorbic acid is "an outstanding antioxidant in blood plasma" against lipid peroxidation, until during the manuscript preparation we learnt this from two highly cited papers that will be discussed later (Frei et al., 1988 (Frei et al., & 1989 .
In an effort to trap the epoxide presumed in our mechanism, GSH was added to rat plasma at 5 mM resulting in a clear decrease in ROP (Table 2) . Importantly, GSH conjugates were not found, but the disappearance of parent was also attenuated (data not shown). This suggests that GSH probably prevents the reaction at the first epoxidation stage. Additional experiments with 50 mM GSH in plasma showed even greater inhibition on both ROP formation (Table 2 ) and AZD9819 depletion (data not shown). GSH is an important antioxidant in biological systems preventing damage by reactive oxygen species such as free radicals and peroxides, in addition to being a strong nucleophile which reacts well with soft electrophiles. GSH-dependent selenoperoxidases catalyze two-electron reduction of lipid peroxides (LOOH) to inert lipid alcohols (LOH), while two reduced GSH molecules become one oxidized GSSG (Girotti, 1998) .
Collectively, these observations led us to consider lipid peroxides as the probable cause for the oxidation of AZD9819 in plasma. Moreover, a lipid peroxide mediated oxidation would incorporate molecular oxygen during the lipid peroxidation chain propagation (Frei et al., 1989; Girotti, 1998) 
and be consistent with our observation
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Finally we succeeded in generating ROP using human low-density lipoprotein (LDL, 1 mg/mL) in pH7.4 buffer ( Figure 5B ). The level of ROP formation was diminished in the presence of 50 mM GSH or ascorbic acid ( Figure 5C and 5D) . Percentages of ROP formation derived from LC-UV peak areas and UV signal response ratio are compared in Figure 5F . This article has not been copyedited and formatted. The final version may differ from this version. 
DISCUSSION
The inhibitive effects of ascorbic acid and GSH on AZD9819 oxidation in both the LDL and plasma incubation provided the supporting evidence to the involvement of lipid peroxides in the oxidation. Frei at al. have previously stated that ascorbate is the only plasma antioxidant that can completely protect plasma lipids against detectable peroxidative damage induced by aqueous peroxyl radicals (Frei et al., 1988 (Frei et al., & 1989 . Additionally, they have demonstrated that protein thiol groups are the second in line for antioxidant defense, while naturally occurring GSH in isolated plasma is present only at a very low concentration (<0.5 µM. Frei et al., 1988) .
Lipid peroxide mediated oxidation explains why ROP was only formed ex vivo and in vitro, since a number of scavengers of lipid peroxyl radicals and lipid peroxides maintain a very low level of lipid peroxides in a living biological system (Frei et al., 1988 (Frei et al., & 1989 Girotti, 1998) . However, those scavengers can be depleted ex vivo allowing the buildup of lipid peroxides by chain propagation. Lipid peroxide mediated oxidation also rationalizes why protein precipitation by acetonitrile abolishes the ROP formation in acetonitrile denatured plasma (Table 2) .
Frei et al. reported that after the depletion of ascorbate in plasma, peroxidation occurred first to lipids transported in lipoproteins, whereas nonesterified fatty acids were still protected from oxidation by binding to plasma albumin (Frei et al., 1988) . In the LDL incubation without plasma albumin, acetronitrile containing 1% formic was used as presumably a better quench solution. Differing levels of pre-existing lipid peroxides would rationalize our observation of variations in ROP formation in different plasma samples of the same species, e.g., number of free/thaw cycles, length of storage time at -18 °C (data not shown).
Future work could include quantitative analysis of lipid peroxides, e.g., to study the relationship between the level of lipid peroxides and the ROP formation, and to investigate factors affecting the level of peroxides in plasma samples. Finally, ROP formation via epoxidation of AZD9819 in plasma is not contradictory to the chemical preparation of ROP using sodium perborate, since sodium perborate functions mainly as a convenient source of mildly alkaline hydrogen peroxide and is a known agent for epoxidation of a wide range of alkenes while also being a known agent of heteroatom oxidation (Mckillop and Sanderson, 2000; Bortolini, 2009 ).
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The level of ROP generated by LDL was enhanced several fold when incubated at pH 10.5 relative to that at pH 7.4 ( Figure 5E vs. 5B; and Figure 5F ). Furthermore, ROP was absent from the LDL incubation in pH 4.5 buffer (data not shown), consistent with the empirical use of acidification to prevent ex vivo oxidation of AZD9819 in plasma samples. No ROP was formed when AZD9819 was incubated in the individual buffer solutions as a control. The calculated pKa (ACD/pKa DB 2012) for an allylic hydroperoxide of a polyunsaturated fatty acid is approximately 11.3 and thus the pH-dependence suggests that a nucleophilic epoxidation of the C=C bond in the pyrazinone ring of AZD9819 (Scheme 2) is highly plausible. It is known that nucleophilic epoxidation by hydroperoxide can occur at alkenes that are conjugated with electron withdrawing groups (Apeloig et al., 1983) .
Interestingly, the addition of 50 mM KCN to the LDL incubation at pH7.4 approximately doubled the formation of ROP (data not shown, but similar to that observed in rat plasma, Table 2 The hydration of the imine in our proposed mechanism is necessary to change the rigid sp2 carbon to a more flexible sp3 centre, thereby allowing intramolecular nucleophilic attack of the carboxamide oxygen on the epoxide (1 to 2, Scheme 1). We also note that an oxygen anion is naturally formed for the proposed ring closure (2, Scheme 1). Previously reported mechanisms for P450-mediated oxidation of a pyrazinone ring are related in that they involve either hydrolysis or GSH addition to an epoxide Subramanian et al., 2003; Zhou et al., 2010) , presumably catalyzed by epoxide hydrolases or glutathione S-transferases present in liver (Parkinson, 2001) . These led to the pyrazinone ring opening by the breakage of one or both C-N bonds resulting in multiple products. Our proposed mechanism, involving a non-enzymatic epoxidation of AZD9819 followed by imine-hydration and subsequent elimination of a water molecule (Scheme 1) leads to a single rearranged product and is therefore consistent with the radiochromatographic data ( Figure 1 ).
The final rearrangement step proposed for intermediates 4 to 5 in Scheme 1 can be viewed as the intramolecular transfer of the negative charge from an apparently high energy anion to a reasonably low energy anion and therefore the formation of a more stable species. The negative charge in 5 can be delocalized by adjacent carbonyl and phenyl groups, whereas the charge in 4 would be delocalized only by the oxazole. Interestingly, intermediate 4 was briefly assumed to be likely structure of ROP before the characterization of ROP by HMBC 2D NMR as shown in Figure 2 . At that time, we had to postulate an acetyl migration rearrangement in gas-phase MS/MS fragmentation in order to interpret a major fragment ion by the neutral loss of a 3-(trifluoromethyl)aniline (m/z 348.11). After which, the HMBC data made us to quickly realize that the rearrangement of acetyl migration had already happened in the formation of ROP.
The deacetyl-ROP that occurred mainly in rat plasma has been shown to be an enzymatic hydrolysis product of ROP (Supplemental Figure 9A) . It is known that hydrolysis of carboxamide in plasma can be mediated by carboxylesterases (Parkinson 2001 ). The species difference in deacetyl-ROP between rat and dog/human ( Figure   1A vs. B & C) can be readily rationalized by the differences in carboxylesterase expression and the hydrolase activity in plasma (Bahar et al., 2012) .
To the best of our knowledge, this is the first reported case of epoxidation of a pharmacological agent by lipid peroxides in plasma. We acknowledge that epoxidation by lipid peroxides is neither a new concept nor a new phenomenon. It is known that lipid epoxides can be generated as secondary oxidation products of lipid peroxidation (Scheick and Spiteller, 1993; Chen and Chung, 1996) . Scheick and Spiteller (1993) plasmalogens. Chen and Chung (1996) reported that two linoleic-acid derived hydroperoxides were capable of epoxidizing a lipid peroxidation product 4-hydroxy-2-nonenal to a mutagenic epoxy aldehyde. Lipid hydroperoxides produced during the peroxidase cycle are also known to be capable of epoxidizing polycyclic aromatic hydrocarbon (PAHs) as an alternative pathway to P450-mediated activation of PAHs to mutagenic epoxides (Parkison, 2001; Reed, 1987) . Additionally, non-P450-catalyzed epoxidation of the terminal furan of aflatoxin B1 (a hepatocarcinogen and hepatotoxin produced by fungal metabolism) was shown to be dependent on the preoxidation of arachidonic acid by prostaglandin H synthase (Parkinson, 2001; Reed, 1987; Battista and Mament, 1985) . The feasibility of epoxidation by lipid hydroperoxides has therefore been demonstrated in the literature.
It seems unlikely that AZD9819 and related compounds are the only xenobiotic analytes susceptible to lipid peroxide-dependant oxidation. In the present study, we have demonstrated two practical, effective means of preventing the oxidation: Lowing the pH to stop the nucleophilic reaction of epoxidation by lipid hydroperoxides, or adding the antioxidant ascorbic acid to inhibit the radical reaction of lipid peroxidation. We hope that knowledge of this new possible cause of analyte instability in plasma samples and the means of prevention will prove useful for other scientists in biotransformation and bioanalysis.
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